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 Diabetic retinopathy (DR), the most prevalent micro-
vascular complication of diabetes, is responsible for over 
10,000 new cases of blindness every year in the United 
States alone ( 1 ). The risk of vision loss increases with the 
development of diabetic macular edema and/or retinal 
neovascularization (NV), the former being a direct con-
sequence of blood-retinal barrier (BRB) dysfunction and 
the latter the result of widespread retinal ischemia ( 2 ). 
 For years, signifi cant effort has been invested in eluci-
dating the mechanisms that underlie destructive prereti-
nal NV in DR ( 3 ). Nonetheless, considerably less is known 
about the molecular events that lead to BRB dysfunction 
that is characterized by enhanced retinal vascular perme-
ability and recruitment of infl ammatory cells. Moreover, 
existing regimens of treatment carry nonspecifi c adverse 
effects. These include increased risk of thromboembolic 
incidence, neuronal toxicity, and geographic atrophy with 
anti-vascular endothelial growth factor (VEGF) therapies 
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 In addition to dyslipidemia, oxidative stress has at-
tracted considerable interest as a key factor in mediat-
ing retinal vascular injury during DR. Our previous 
studies highlighted NADPH oxidase (NOX) as a major 
source of ROS generation in the retinas of experimen-
tal diabetic rodents and OIR models, as well as in retinal 
endothelial cells treated with high glucose (HG) or hy-
poxia ( 23–26 ). Our recent study showed that inhibiting 
12/15-LOX by baicalein reduced diabetes-induced ROS 
generation and NOX2 expression in mouse retina, sug-
gesting the existence of an interconnected signaling be-
tween LOXs and NOX ( 22 ). However, the cross-talk 
between NOX and infl ammatory bioactive lipids re-
mains ill-defi ned in DR. 
 Therefore, the current study has been taken up to char-
acterize the effect of hyperglycemia on bioactive-lipid 
profi le in human retinal endothelial cells (HRECs) to de-
termine whether endothelial cells are a potential source of 
12/15-LOX-derived hydroxyeicosanoids, and whether 
these metabolites play a causative role in the pathogenesis 
of BRB dysfunction during diabetes. Furthermore, the 
present work aimed to gain insights into the underlying 
molecular mechanisms by portraying the causal relation-
ship with NOX. 
 RESEARCH DESIGN AND METHODS 
 Animal preparation and experimental design 
 All procedures with animals were performed in accordance 
with the Public Health Service Guide for the Care and Use of 
Laboratory Animals (Department of Health, Education, and 
Welfare publication, National Institutes of Health 80-23) and 
Georgia Regents University guidelines. Six to eight-week-old 
male 12/15-LOX knockout (LOX   /   ) mice lacking the NOX2 
subunit of NOX (NOX2   /   ), and corresponding littermate 
controls, WT mice in C57BL/6J background (Jackson Labora-
tory, Bar Harbor, ME), were matched according to sex, age, and 
weight. Animals were given intraperitoneal injections of freshly 
prepared streptozotocin (45 mg/kg; Enzo Life Sciences) dis-
solved in 0.9% NaCl after 4 h fasting for fi ve consecutive days. 
Mice with blood glucose levels >300 mg ⁄dl were considered dia-
betic. Six weeks after establishment of diabetes, retinal vascular 
permeability was evaluated using fl uorescein angiography. 
Thereafter retina samples were used for total albumin analysis 
by Western blot. 
 For intravitreal injections, the procedure was essentially the 
same as previously described ( 27 ). To avoid uncontrolled intra-
ocular pressure increase, the volume of intravitreal injections 
was limited to 1   l. 12-HETE was dissolved in ethanol and a 
working solution of 10× was prepared by diluting 0.32   l of 
stock solution (312   M) to 100   l with PBS, assuming the vitre-
ous volume of mouse eye is   10   l ( 28 ). Then by injecting 1   l 
of this working solution, a 0.1   M vitreal concentration of 12-
HETE was obtained. The vitreal concentration of ethanol was 
0.032%. The volume of the injected solution apparently did not 
cause signifi cant pressure-induced retinal damage, because 
0.032% ethanol-PBS-injected control eyes showed normal reti-
nal morphology with no apparent apoptosis within 7 days. The 
dose of 12- or 15-HETE was chosen according to what was de-
tected previously in the vitreous of patients with DR, 50 ng/ml 
(  0.1   M) ( 21 ). 
( 4, 5 ). Likewise, cumulative risks of cataract and glaucoma, 
as well as local immunosuppression, are frequently associ-
ated with corticosteroid intravitreal therapy ( 6, 7 ). Even 
with laser-based photocoagulation, the gold standard 
treatment for DR, side effects ranging from blurred pe-
ripheral vision to scotomas may occur ( 8 ). These thera-
peutic limitations impose the necessity for novel therapeutic 
interventions via unraveling the pathophysiology of DR. 
 In recent years, human studies have underscored the 
strong association between dyslipidemia and the devel-
opment of DR. Clinically, it has been reported that the 
severity of retinopathy in type 1 diabetes was correlated 
positively with triglyceride level and negatively with the 
HDL concentration ( 9 ). Additionally, intensive dyslipid-
emia therapy signifi cantly slowed the progression of DR 
in type 2 diabetes over 4 years ( 10 ). Diabetic dyslipidemia 
is characterized by a shift in the fatty acid profi le with an 
increase in omega-6 PUFAs, in particular arachidonic acid 
(AA), released from membrane lipids by the activated 
phospholipase A2 (PLA2) ( 11, 12 ). The released AA, in 
turn, can be converted to infl ammatory bioactive lipid me-
diators such as HETEs, leukotrienes, and prostaglandins 
via different enzymatic pathways including cycloxygenase, 
lipoxygenase (LOX), and cytochrome P450 ( 13 ). 
 Bioactive lipids activate specifi c signaling pathways that 
are implicated in cell proliferation, differentiation, and 
apoptosis. Sustained cellular response to increased bioac-
tive lipids becomes pathological and results in chronic dis-
eases such as cancer and atherosclerosis ( 14 ). 
 While there is irrefutable evidence for the role of 
dyslipidemia in the progression of DR ( 9, 15 ), bioactive 
lipid metabolites have received limited attention. HETEs 
are major monohydroxylated AA bioactive lipid metabo-
lites that are produced during infl ammatory and immuno-
logical reactions ( 16 ). The 12- and 15-HETEs are formed 
by human 15-LOX and its murine ortholog 12/15-LOX 
( 17 ) in a variety of mammalian cells such as endothelial 
cells, eosinophils, and epithelial cells to exhibit distinct 
biological activities. These activities include stimulation of 
endothelial cell mitogenesis, vascular infl ammation, and 
mucus release from human airways ( 18–20 ). Recently, we 
have shown that pharmacological inhibition or deletion of 
12/15-LOX reduces retinal NV in the oxygen-induced 
retinopathy (OIR) model ( 21 ). Moreover, we have demon-
strated in both human patients and animal models that 
retinal expression of 12/15-LOX is robustly induced dur-
ing diabetes ( 21 ). At the same time, its pharmacological 
inhibition dampened the levels of infl ammatory cytokines, 
reactive oxygen species (ROS) gener ation, and phosphor-
ylated VEGF receptor 2 expression in the retinas of dia-
betic mice ( 22 ). However, the cellular source of these lipid 
metabolites is unknown and could be derived from retinal 
tissues, including the retinal vascular endothelial, glial, 
and pigmented epithelial cells, as well as from infi ltrated 
infl ammatory cells. Moreover, the role of 12- or 15 HETE 
in mediating the breakdown of barrier function, such as 
that observed in DR, has not been investigated thoroughly 
to date. 
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4°C. The next day the sections were incubated in Oregon green-
labeled anti-rabbit antibody. Sections were covered using DAPI 
mounting medium and images were obtained with confocal mi-
croscopy (LSM 510; Carl Zeiss). 
 Fluorescein angiography 
 The anesthetized mouse was placed on the imaging platform 
of the Phoenix Micron III retinal imaging microscope and Go-
niovisc 2.5% was applied liberally to keep the eye moist during 
imaging. Mice were administered 10 to 20   l 10% fl uorescein 
sodium and rapid acquisition of fl uorescent images ensued for 
  5 min, as previously described ( 33 ). 
 Protein extraction and Western blot analysis 
 Cell or retinal lysates were subjected to Western blot analysis 
using antibodies for 15-LOX1 (Novus biologicals, Littleton, CO), 
5-LOX and   -actin (Millipore Corporation, Billerica, MA), 
VCAM-1 and ICAM-1 (Cell Signaling Technology, Beverly, MA), 
albumin (Bethyl, TX), NOX2 (BD Biosciences, Franklin Lakes, 
NJ), and CD45 (Santa Cruz, CA) according to a previous proce-
dure ( 27 ). 
 RNA interference 
 HRECs were transfected with NOX2 or control Dicer-substrate 
RNA duplexes (catalog number HSC.RNAI.N000397.12, Inte-
grated DNA Technologies) using lipofectamine 2000 per the 
manufacturer’s instructions. 
 In vitro leukocyte adhesion assay 
 HRECs were grown to confl uence in 12-well plates then 
treated with or without 15-HETE (0.1   M) in the presence or 
absence of apocynin (30   M) or NAC (50   M), as well as with 
positive control, 10   g/ml of the endotoxin  Escherichia coli lipo-
polysaccharide (Sigma-Aldrich, St. Louis, MO) for 24 h. Follow-
ing the treatment, leukocytes (300,000–400,000 cells/well) 
 Microvascular HRECs 
 In vitro experiments were performed using cultured HRECs 
(Cell Systems Corporation). After the cells were 80–90% confl u-
ent, they were serum starved (2% FBS) overnight, then treated 
with 15-HETE (0.1   M) with or without apocynin (30   M) or  N -
acetyl-L-cysteine (NAC) (50   M), or HG (D-glucose, 30 mM) in 
the presence or absence of 20   M of AA. The osmolarity of the 
control group in the HG experiments was adjusted using L-glucose. 
Cytotoxicity of tested inhibitors was assessed by MTT assay as 
previously described ( 29 ). Transcellular electrical resistance (TER) 
and cell migration were done using electric cell-substrate imped-
ance sensing (ECIS) (Model 1600R, Applied BioPhysics) as previ-
ously described ( 30, 31 ). The experiment was terminated after 
24 h of 15-HETE treatment for analysis of leukocyte adhesion 
and tube formation. Conditioned media were used for multiplex 
assay of various cytokines as previously described ( 30 ). Meanwhile, 
the HG experiment was terminated 5 days after initiation of treat-
ment and cell lysates were collected and analyzed for 15-LOX 
and 5-LOX protein expression using Western blot analysis. At the 
same time, collected cell lysates were assayed for PLA2 activity 
according to manufacturer’s instructions (Cayman, Ann Arbor, 
MI). For lipidomic analysis, the cells were incubated in indicator-
free media for 5 days and then collected with cells together, soni-
cated, centrifuged to remove cell debris, and then frozen for the 
analysis in the Lipidomics Core Facility (Wayne State University, 
Detroit, MI) as described before ( 32 ). 
 Immunofl uorescence 
 Retinal paraffi n sections of human subjects with or without DR 
obtained from Capital Bioscience (Rockville, MD) were fi xed in 
10% neutral buffered formalin. Following rehydration of the par-
affi n section and two washes in PBS, sections were treated with 
proteinase K for 10 min and washed twice in PBS followed by 
blocking with 10% normal goat serum and then incubated with 
phospho-PLA2 antibody overnight in a humidifi ed container at 
 TABLE 1. Nondetectable lipid metabolites in the lipidomic profi le of HRECs under hyperglycemia 
Number Lipid Metabolite Number Lipid Metabolite Number Lipid Metabolite
1 9-OxoOTrE 26 PGF1a 51 8,9-EpETrE
2 15d-D12,14-PGJ2 27 13,14dhPGE1 52 16(17)-EpDPE
3 5-HEPE 28 7(S)-Maresin1 53 19(20)-EpDPE
4 12-OxoETE 29 PD1 54 D17-PGE1
5 5-oxoETE 30 4,17-DiHDoHE 55 8-isoPGF2a
6 15-OxoETE 31 7,17-DiHDPE 56 11bPGF2a
7 5,6-EpETrE 32 11dh TXB3 57 7(8)-EpDPE
8 5(S)-HETrE 33 20-COOH LTB4 58 10(11)-EpDPE
9 15-OxoEDE 34 6-keto PGE1 59 13(14)-EpDPE
10 15(S)-HEDE 35 11dh-TXB2 60 RvD2
11 tetranor PGEM 36 TXB3 61 RvD5
12 5,6-DiHETE 37 19(R)-OH PGE2 62 RvE3
13 5(S),6(S)-DiHETE 38 6kPGF1a 63 PGA1
14 5(S),15(S)-DiHETE 39 19(R)-OH PGF2a 64 LTC4
15 Bicyclo PGE1 40 6,15-diketo PGFa 65 LTD4
16 5,6-DiHETrE 41 19(R)-hydroxy PGE1 66 LTE4
17 8,9-DiHETrE 42 RvD1 67  N -acetyl LTE4
18 11dh-2,3-dinor TXB2 43 8,9-EpETE 68 9-HEPE
19 2,3-dinor TXB2 44 14,15-EpETE 69 13,14dh-15k-PGF2a
20 RvE1 45 17,18-EpETE 70 11(R)-HEDE
21 LXA5 46 15-keto PGF2a
22 15-keto PGE2 47 13,14dh-15k-PGE2
23 PGF3a 48 15-keto PGE1
24 20-hydroxy LTB4 49 13,14dh-15k-PGE1
25 LXA4 50 PGE1
DiH, dihydroxy; DoHE, docosahexaenoic acid; DPE, docosapentaenoic acid; EDE, eicosadienoic acid; Ep, 
epoxy; EPE, eicosapentaenoic acid; ETE, eicosatetraenoic acid; ETrE, eicosatrienoic acid; H, hydroxyl; LX, lipoxin; 
LT, leukotriene; OTrE, octadecatrienoic acid; PD, neuroprotectin; PG, prostaglandin; tetranor PGEM, tetranor-
prostaglandin E metabolite; RV, resolvin;TX, thromboxane. 
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 Data analysis 
 The results are expressed as mean ± SD. Differences among 
experimental groups were evaluated by using the two-tailed  t -test 
or one-way ANOVA. When statistical differences were observed 
using ANOVA, a post hoc Tukey’s test was performed to deter-
mine which groups differed. 
 The Bonferroni correction factor (BCF), which accounts for 
a large number of comparisons by reducing the   level as to 
decrease the probability of obtaining a type I error, was used 
when analyzing lipid metabolite profi les among groups. BCF 
was calculated by dividing the   level (0.05) by the number of 
bioactive lipid metabolites detected. Because 56 individual me-
tabolites were detected, the new   value used for individual me-
tabolites was 0.0009 (0.05/56 ). A new   level of 0.0055 (0.05/9) 
was also calculated for the top 15% of metabolites which are 
used for further analysis by measuring their profi le in the pres-
ence of exogenous AA as a substrate under hyperglycemic 
conditions. 
 Differences were considered statistically signifi cant if  P < 0.05, 
except for lipid metabolites, which used the   values calculated 
from the Bonferroni correction. 
purchased from Sanguine Bioscience (Valencia, CA) and labeled 
with diluted LeukoTracker solution (Cell Biolab) for 60 min at 
37°C, according to the manufacturer’s instructions, were added 
to confl uent monolayer HRECs and incubated for 90 min at 
37°C. Immediately before the assay, nonadherent cells were re-
moved by washing three times with RPMI-1640 medium (Life 
Technology, Grand Island, NY). The adherent labeled leuko-
cytes were counted under the inverted fl uorescence microscope 
at 480 nm/520 nm from three separate fi elds per well. 
 In vitro endothelial tube formation on Matrigel 
 Tube formation assay was done as described before ( 34 ). 
Briefl y, vehicle or 15-HETE (0.1   M) in the presence or absence 
of different inhibitors, was added to the appropriate wells and 
the cells were incubated at 37°C overnight. Tube formation was 
observed under an inverted microscope and the images were cap-
tured with a digital camera attached to the microscope. The mea-
surement was done on three randomly chosen microscopic fi elds 
per well, and the mean of the three fi elds was used as a single 
observation. Tube formation was further quantifi ed by measur-
ing the total length of tube-like cells using ImageJ software. 
 Fig.  1. Characterizing the effect of hyperglycemia on altering the bioactive-lipid profi le in HRECs using LC/MS. A: Fold change in the 
lipidomic profi le of HRECs under hyperglycemia, D-glucose (30 mM) for 5 days, compared with normo-osmotic control, D-glucose (5 mM) 
plus L-glucose (25 mM). B: Fold change of upregulated metabolites detected in the previous screen in the presence or absence of exoge-
nous AA (20   M) under hyperglycemia compared with the corresponding controls, D-glucose (5 mM) plus L-glucose (25 mM), with or 
without AA (20   M). Data shown are the mean ± SD of three independent experiments . DiH, dihydroxy; DoHE, docosahexaenoic acid; 
DoPE, docosapentaenoic acid; EDE, eicosadienoic acid; Ep, epoxy; EPE, eicosapentaenoic acid; ETE, eicosatetraenoic acid; ETrE, eicosa-
trienoic acid; H, hydroxyl; IP, isoprostane; LT, leukotriene; LX, lipoxin; ODE,  octadecadienoic acid; OME,  octadecenoic acid; OTrE, 
octadecatrienoic acid; PG, prostaglandin; TX, thromboxane. 
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 RESULTS 
 Hyperglycemia alters bioactive-lipid profi le in HRECs 
 In order to evaluate the potential role of bioactive lipids 
in mediating the edematous phenotype observed in DR, 
we fi rst sought to characterize their profi le under diabetic 
milieu. In this regard, the lipidomic profi le of HRECs was 
screened for metabolites whose levels changed dramati-
cally during hyperglycemia. Out of 126 bioactive lipids 
screened, 70 were not detectable ( Table 1 ), 47 did not 
change signifi cantly ( t -test,  P > 0.05), and 9 metabolites 
were increased ( t -test,  P < 0.05) under hyperglycemic con-
ditions (30 mM D-glucose) compared with the normo-
osmotic control (5 mM D-glucose + 25 mM L-glucose) 
( Fig. 1A ).  However, after the Bonferroni correction, the 
fold changes in the level of eight metabolites among the 
nine increased were statistically not signifi cant, and only 
15-HETE had a signifi cant fold increase (2.4 ± 0.4) with a 
 P value of 0.0004 (BCF   = 0.0009). Next, we narrowed our 
focus to confi rm these data, considering the top 15% of 
the upregulated metabolites detected in this screen . By 
measuring their profi le in the presence of exogenous AA 
as a substrate under hyperglycemic conditions, we found 
a signifi cant increase in AA-derived eicosanoids gener-
ated by the 12/15-LOX pathway including: 15-HETE 
(BCF   = 0.0055, Tukey’s post hoc,  P = 0.001), 11-HETE 
(BCF   = 0.0055, Tukey’s post hoc,  P = 0.0001), and 12-
HETE (BCF   = 0.0055, Tukey’s post hoc,  P = 0.001) in 
which 15-HETE again had the highest (5.48 ± 1.12) fold 
increase. On the other hand, the levels of other non-AA-
derived metabolites [8-, 13-, 16-, and 17-hydroxydocosa-
hexaenoic acid (HDoHE) and 13-HODE] did not change 
signifi cantly in the presence of exogenous AA with the ex-
ception of 13-HODE,  Fig. 1B . 
 Western blot analysis of LOXs from HRECs further cor-
roborated data obtained by LC/MS metabolite measure-
ment. Results revealed that 15-LOX protein expression 
was signifi cantly increased by 2.5-fold after treating HRECs 
with HG compared with control. Meanwhile, the protein 
expression level of 5-LOX did not change signifi cantly un-
der the same treatment,  Fig. 2A . Given the prominent in-
crease in levels of 15-HETE under the hyperglycemia, we 
proceeded to investigate the propensity of 15-HETE to 
disrupt vascular barrier function in the HREC monolayer 
using real-time analysis of TER, an indicator of mono-
layer integrity. We tested the concentration of 15-HETE 
 Fig.  2. Hyperglycemia induced 15-LOX protein expression as well as PLA2 activity. A: HRECs were treated with HG, D-glucose (30 mM), 
or normo-osmotic control for 5 days. Western blot was performed as described in the Research Design and Methods using 15-LOX, 5-LOX, 
and actin antibodies followed by densitometric analysis. Ratio of the band intensity of 15-LOX or 5-LOX relative to the actin was reported 
as fold increase in relation to normo-osmotic control (L-glucose), which was arbitrarily set at 1.0. B: HRECs were treated with 15-HETE or 
vehicle and the change in the resistance was monitored as described in Research Design and Methods using ECIS. Normalized TER for 
15-HETE treatment was compared with vehicle-treated endothelial monolayer. C: Treatment of HRECs with D-glucose (30 mM) for 5 days 
stimulated the activity of PLA2 compared with normo-osmotic control. Data shown are the mean ± SD of three independent experiments. 
D: In vivo detection of phosphorylated PLA2 (pPLA2) (active form) in serial sections from human diabetic or normal retinas around blood 
vessel regions (yellow arrowhead), perivascular in the area of glial cells, detected by its marker, glial fi brillary acidic protein (GFAP) (white 
arrows), as well as in the outer segment of the photoreceptors (yellow arrow). 
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 Fig.  3. Evolving role of 12/15-LOX in compromising retinal barrier function during diabetes. A: Fluorescein angiography (FA) of nor-
mal WT, normal 12/15-LOX   /   , diabetic WT, and diabetic 12/15-LOX   /   mice together with their binary images. Data are representative 
pictures taken at constant interval of every mouse studied in each group. The fl uorescence intensity of FA per mouse retina was calculated 
by the ImageJ software after conversion to binary images then normalized to that of normal WT, which was arbitrarily set at 100. B: Western 
blot of total retinal albumin among the studied groups followed by densitometric analysis. Ratios of albumin band intensities relative to the 
actin for each group were compared with normal WT control, which was arbitrarily set at 1.0. Data shown for the comparison are the mean 
± SD of four to six mice studied in each group. 
that had been detected in the vitreous of patients with DR, 
  55 ng/ml (0.1–0.3   M) ( 21 ) and shown by us to elicit 
transcellular leakage of FITC-dextran in bovine retinal en-
dothelial cells ( 22 ). Changes in TER were fi rst observed 
after 26 h of 15-HETE treatment and continued to de-
crease throughout the experiment period,  Fig. 2B . 
 These data presumably refl ect a PLA2-dependent path-
way in releasing endogenous free AA as the mediator’s 
precursor followed by the activation of metabolizing LOXs. 
To this end, we determined the in vitro endothelial PLA2 
activity in response to diabetic conditions. As depicted in 
 Fig. 2C , treatment of HRECs with hyperglycemia for 5 
days stimulated the activity of PLA2 by 2-fold compared 
with control. This fi nding of increased PLA2 activity has 
been substantiated by the detection of phosphorylated 
PLA2 (active form) in diabetic human retinal sections 
( Fig. 2D ). Phosphorylated PLA2 was mostly localized in 
the endothelial layer of the retinal vessels and perivascu-
lar retinal glial cells, as well as in the outer segment of the 
photoreceptors. 
 Evolving role of 12/15-LOX pathway in compromising 
retinal barrier function during diabetes 
 The aforementioned data from lipidomic analysis pro-
vide a rationale to explore the role of the 12/15-LOX 
pathway in diabetes-induced BRB breakdown. We used 
two complementary approaches for this investigation. The 
fi rst approach was aimed to assess whether knocking out 
retinal 12/15-LOX, an ortholog of human 15-LOX1 ( 17 ), 
would effi ciently reduce the pathological vascular perme-
ability seen in DR. To achieve this goal, we used the well-
defi ned 12/15-LOX (Alox15) knockout mice and matched 
congenic controls. First, these mice were regenotyped be-
fore the study to ensure that they had deletion of 12/15-
LOX in the retina according to the Jackson Laboratory’s 
protocol (data not shown). Next, streptozotocin was ad-
ministered to   6-week-old mice and blood glucose was 
monitored. Mice were considered diabetic if their non-
fasted glucose level was higher than 300 mg/dl. After 
6 weeks, the magnitude of retinal vascular leakage was 
assessed via a clinical diagnostic technique, fl uorescein an-
giography. At this time point, fl uorescein angiography 
from WT diabetic mice exhibited a signifi cant elevation, 
almost 2.5-fold in fl uorescein hyper-fl uorescence com-
pared with the nondiabetic littermates. In contrast, the 
increase in fl uorescein hyper-fl uorescence was signifi -
cantly lowered to 1.9-fold by knocking out 12/15-LOX, 
 Fig. 3A . To further confi rm the role of the 12/15-LOX 
pathway in mediating diabetes-induced vascular permea-
bility, Western blot analysis of total retinal albumin was 
performed. As shown in  Fig. 3B , the total retinal albumin 
content in diabetic WT mice was 4-fold higher than that in 
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nondiabetic WT mice. However, knocking out 12/15-LOX 
resulted in a 59% reduction of total albumin in the retinas 
of diabetic mice. 
 Further evidence for the ability of 12/15-LOX to com-
promise endothelial barrier function was obtained from 
our second approach. In this approach, an in vivo experi-
mental eye model was used in which normal mice were 
injected intravitreally with a 12/15-LOX-derived predomi-
nant murine metabolite, 12-HETE, into the right eye and 
vehicle into the left eye. Thereafter, the putative biological 
effect of 12-HETE per se on retinal permeability was pho-
tographically seen via fl uorescein angiography. As shown 
in  Fig. 4A , a marked increase in fl uorescein leakage was 
observed in eyes receiving 12-HETE compared with the 
vehicle-injected contralateral eyes. Concordantly, Western 
blot analysis for total retinal albumin was performed to 
further corroborate 12-HETE’s ability to induce vascular 
permeability. As shown in  Fig. 4B , 12-HETE injection in-
duced a signifi cant 2.8-fold increase in total retinal albu-
min compared with vehicle-injected controls. 
 The effect of 12-HETE on retinal vasculature was 
characterized by a marked increase in the infl ammatory 
response 
 We next sought to determine whether the deleterious ef-
fect of 12-HETE on retinal vasculature was associated with a 
pro-infl ammatory phenotype (increased adhesion molecule 
expression and leukocyte adhesion). To address this point, 
we determined the effect of 12-HETE injection on retinal 
levels of ICAM-1 and VCAM-1, well-established markers of 
endothelial dysfunction in infl ammatory conditions ( 35 ). 
Western blot analysis of ICAM-1 showed a 2.9-fold increase 
in 12-HETE-injected eyes compared with vehicle-injected 
contralateral eyes. Likewise, the retinal VCAM-1 level was 
higher (2.5-fold,  P < 0.05) in 12-HETE-injected eyes than in 
control. Furthermore, the infl ammatory response to the in-
travitreally injected 12-HETE was determined by leukocyte 
infi ltration as assessed by CD45, a common infl ammatory 
leukocyte antigen. A signifi cant increase in CD45 immuno-
reactivity (1.4-fold) in the retinas of 12-HETE-injected eyes 
was observed compared with control ( Fig. 4C ). 
 Fig.  4. Direct effects of 12/15-LOX-derived metabolites on retinal vasculature. A: Fluorescein angiography (FA) of normal WT mice in-
jected intravitreally with vehicle, as a control, or 12-HETE. One week later, FA was performed to evaluate changes of retinal vasculature. 
The relative fl uorescence intensity of FA per mouse retina was calculated by the ImageJ software then normalized as a percentage to that 
of vehicle-injected control, which was arbitrarily set at 100%. B: Western blot of total retinal albumin among the studied groups followed 
by densitometric analysis. Ratio of the albumin band intensity relative to actin for the 12-HETE-injected group was compared with the 
vehicle-injected control, which was arbitrarily set at 1.0. C: Western blot analysis of retinal ICAM-1, VCAM-1, CD45, and NOX2 after intra-
ocular injection with either 12-HETE (0.1 µM), or vehicle followed by densitometric analysis. Ratios of band intensities of ICAM-1, VCAM-1, 
CD45, and NOX2, respectively, relative to the actin for 12-HETE-injected group were compared with the vehicle-injected control, which 
was arbitrarily set at 1.0. Data shown for the comparison are the mean ± SD and representative of four to six mice studied in each group. 
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 Fig.  5. 12-HETE or 15-HETE activates HRECs for leukocyte adhesion in a NOX-dependent manner. A: Multiplex analysis of cytokine and 
chemokine production in conditioned media of HRECs treated with vehicle or 12- or 15-HETE (0.1   M), n = 4. B: Reduction of 15-HETE-
induced leukocyte adhesion by inhibiting ROS derived from NOX. HRECs were seeded in 24-well plates and treated with 15-HETE (0.1   M, 
24 h) or vehicle, in the presence or absence of apocynin (30   M) or NAC (50   M). Representative photomicrographs for adherent leuko-
cytes among studied groups; vehicle-treated control, lipopolysaccharide as a positive control, 15-HETE, 15-HETE + apocynin, and 15-HETE 
+ NAC, were taken and quantifi ed for adherent leukocytes. Quantitative data for adherent leukocytes (labeled with red fl uorescence 
dye) were expressed as the mean number of adherent cells per 100   m ± SD. Numbers represent the average of three independent 
experiments. 
 Intravitreal injection of 12-HETE increased retinal 
expression of NOX2 
 Previous studies, including those from our laboratory, 
have pointed out that NOX-derived ROS have a central 
role in both endothelial and leukocyte activation, keys of 
the retinal infl ammatory paradigm ( 25, 36 ). Therefore, a 
causal relationship between 12-HETE and NOX in mediat-
ing endothelial dysfunction was investigated. To accom-
plish this, we fi rst assessed the question of whether the 
retinal expression of NOX2 is enhanced by intravitreal 
injection of 12-HETE or not. As shown in  Fig. 4C , the 
NOX2 protein level was increased 1.7-fold in the retinas of 
12-HETE injected eyes compared with contralateral con-
trols, implying an existing causal relationship. 
 12/15-LOX lipid metabolites induce HREC activation/
dysfunction in a NOX-dependent manner 
 Guided by the aforementioned results, the role of the 
NOX-dependent pathway in 15-HETE-mediated endothe-
lial dysfunction was tested in depth using a cell culture 
model of HRECs. With this model, incubation with either 
12-HETE or 15-HETE signifi cantly activated endothelial 
cells to release multiple pro-infl ammatory cytokines and 
chemokines. Among these, IL-6, IL-8, IL-17, and MCP-1 
appear to dominate ( Fig. 5A ). To ensure that 12- or 
15-HETE-activated endothelial cells exhibited features of 
microvascular dysfunction characterized by augmentation 
of polymorphonuclear leukocyte (PMN) adherence, we 
performed leukocyte adhesion assays. Exposure of HRECs 
to 15-HETE for 24 h signifi cantly augmented the number 
of PMNs adhering to HRECs (5.9-fold increase) compared 
with control. Next, we tested the role of NOX-derived ROS 
in 15-HETE-induced leukostasis by using apocynin, a NOX 
inhibitor, to inhibit ROS generation, as well as NAC (a 
ROS scavenger) to eliminate ROS as they were generated. 
When apocynin or NAC was added before 15-HETE, the 
number of adherent leukocytes induced by 15-HETE 
dropped back to normal ( Fig. 5B ). To ensure that these 
effects were not caused by nonspecifi c cytotoxicity of apoc-
ynin or NAC, we assessed cell viability in HRECs after 24 h 
exposure to apocynin or NAC, using the MTT assay. Apoc-
ynin or NAC, at the concentration used, did not affect 
HREC viability (94 ± 4% vital cells), indicating that the 
decrease in the number of adherent leukocytes to 










12/15-Lipoxygenase-derived metabolites and DR 607
12-HETE-injected WT littermates ( Fig. 8 ). Taken together, 
these results confi rm that NOX is involved in the 12-HETE-
induced disruption of the inner BRB integrity. 
 DISCUSSION 
 The current therapeutic interventions to treat DR still 
rely heavily on controlling systemic hyperglycemia. How-
ever, many diabetic patients develop retinopathy despite 
having a good control ( 37 ). Furthermore, the recent 
targeted treatments strategies, corticosteroids, and anti-
VEGF therapies, as well as laser photocoagulation, are lim-
ited by their off-target effects. Therefore, it is worthwhile 
to explore new therapeutic avenues to improve DR. To the 
best of our knowledge, the current study provides the fi rst 
preclinical evidence pertaining to the involvement of 
12/15-LOX-derived bioactive lipid metabolites in the 
pathogenesis of vascular barrier breakdown in the early 
stages of DR. Effectively, our study is the fi rst to screen the 
bioactive lipid profi le in HRECs under hyperglycemic con-
ditions. The key fi ndings of this screen are:  1 ) The products 
of the 12/15-LOX pathway were signifi cantly upregulated 
under hyperglycemic conditions with 15-HETE exhibiting 
the most signifi cant increase.  2 ) 15-HETE activates retinal 
endothelial cells through the NOX system leading to in-
creases in leukocyte adhesion, hyperpermeability, and fi -
nally NV, the cardinal signs of DR. 
 LOX is an enzyme that catalyzes the addition of oxygen 
to PUFAs containing 1,4-pentadiene structure. The most 
common analogs are 5-LOX, 12-LOX, and 15-LOX, with 
the number indicating at which carbon the oxygen is in-
serted. Of note, species-specifi c differences between or-
thologous LOX isoforms have been described for the 
murine 12-LOX, which is an arachidonate 15-LOX in hu-
mans. This difference indicates that care should be taken 
if experimental data on LOX metabolism are being trans-
ferred from one species to another ( 38, 39 ). Accordingly, 
15-HETE-activated HRECs was indeed consecutive to inhi-
bition of NOX activity, but not to cell death. 
 In addition to stimulation of leukostasis by 15-HETE, it 
also promoted retinal endothelial angiogenesis. This is 
clearly depicted in two representative in vitro angiogenic 
assays, capillary-like structure formation, and cell migra-
tion ( Figs. 6, 7 ). As shown in  Fig. 6A and quantifi ed in  Fig. 
6B , the length of capillary-like structure formed by HRECs 
in the presence of 15-HETE was signifi cantly increased by 
4-fold compared with control. To investigate the contribu-
tion of NOX in the formation of capillary-like structure 
induced by 15-HETE treatment, NOX inhibitors were 
added to HRECs before 15-HETE treatment. Thereafter, 
the mean length of tubes between cells was measured. We 
found that apocynin, as well as NAC, signifi cantly abro-
gated 15-HETE-induced tube formation. Similarly, 15-
HETE signifi cantly increased HREC migration rate, an 
early step in angiogenesis. This is graphically shown in  Fig. 
7A , where the capacitance of all treated cells was increased 
from   1 nF to 3 nF, wounding phase, then recovered at 
differential rates during the migration, healing phase. The 
mean migration rate of HRECs treated with 15-HETE was 
signifi cantly higher ( P < 0.01) than the rate obtained with 
vehicle-treated control. Whether or not NOX is involved 
in 15-HETE-induced endothelial cell migration was then 
investigated using two complementary approaches. First, a 
NOX inhibitor, apocynin, signifi cantly inhibited 15-HETE-
induced HREC migration without affecting cell viability 
( Fig. 7A ). Second, HRECs were transiently transfected 
with NOX2 siRNA or scrambled siRNA ( Fig. 7B, C ) and 
then treated with 15-HETE as before. NOX2 siRNA, but 
not scrambled siRNA, significantly inhibited 15-HETE-
induced HREC migration ( Fig. 7D ). 
 To further understand the contribution of NOX in me-
diating endothelial barrier dysfunction induced by 12/15-
LOX lipid metabolites, we injected 12-HETE intravitreally 
into NOX2   /   mice. At 1 week after injection, retinal fl uo-
rescein leakage of NOX2   /   mice was statistically less than 
 Fig.  6. 15-HETE promotes angiogenesis of HRECs 
through NOX. A: Representative photomicrographs 
for capillary tube formation among studied groups; 
vehicle-treated control, VEGF as a positive control, 
15-HETE, 15-HETE + apocynin, and 15-HETE + NAC. 
B: Quantitative data for endothelial cell tube forma-
tion expressed as the mean length of formed tube 
microns ± SD. HRECs were seeded in 96-well plates con-
taining matrigel, and treated with 15-HETE (0.1   M, 
24 h) or vehicle, in the presence or absence of apoc-
ynin (30   M) or NAC (50   M). Numbers represent 
average data from three separate experiments. 
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 Fig.  7. 15-HETE induces HREC migration via NOX-dependent pathway . A: Real-time measurement of HREC migration under 15-HETE 
treatment in the presence of apocynin (Apo.) (30   M) or DMSO using ECIS. The migration velocity was calculated by dividing the total 
distance that HRECs moved on the radius of the electrode, which is 125   m the time required for recovering 1 nF capacitance, the confl u-
ence point, then normalized as a percentage relative to the migration rate obtained from vehicle-treated cells, which was arbitrarily set at 
100%. B–D: Inhibition of 15-HETE-induced HREC migration by NOX2 siRNA. Cells were transfected with siRNA or scrambled siRNA for 
24 h and then treated with 15-HETE for 15 min before wound induction. B: Fluorescent detection of transfection control duplex siRNA 
(TYE 563 fl uorescently labeled) in living HRECs 24 h posttransfection. C: Measurement of NOX2 expression relative to actin by Western 
blot after transfection with NOX2 siRNA. D: Real-time measurement of HREC migration under 15-HETE treatment in the presence of 
NOX2 siRNA or scrambled siRNA using ECIS. Relative migration velocity of 15-HETE-treated HRECs in the presence or absence of NOX2 
siRNA was normalized as a percentage to that of vehicle with scrambled siRNA-treated cells, which was arbitrarily set at 100%. Data shown 
are the mean ± SD of three independent experiments. 
we have used 12-HETE in all murine experiments versus 
15-HETE in all human cell experiments. Although a large 
body of data indicates that LOX plays a role in the patho-
genesis of various diseases, including cancer and athero-
sclerosis, novel physiological roles continue to emerge. In 
relation to retinal vasculopathies, LOXs present them-
selves as attractive candidates for therapeutic targeting. 
This input has originated partly from pathological studies 
showing the elevated level of 15-HETE in epiretinal mem-
branes of proliferative vitreoretinal and proliferative DR 
patients ( 40 ). These initial observations have been sup-
ported by LC/MS analysis of HETEs in biopsied vitreous 
samples from diabetic subjects ( 41 ), and reinforced in 
postmortem human retinas by additional pathological 
studies showing a marked increase in the protein levels of 
both leukocyte and platelet 12/15-LOX in diabetics com-
pared with nondiabetics ( 21 ). Furthermore, it has been 
demonstrated that 5- or 12-LOX deletion reduces diabe-
tes-induced leukostasis. However, deletion of 5-LOX, but 
not 12-LOX, reduced capillary degeneration ( 42 ), sug-
gesting that 5-, 12-, and 15-HETE are each required for 
different stages of DR. Additionally, we have previously 
demonstrated in a model of OIR that 12/15-LOX and its 
products are important regulators of retinal NV through 
modulation of VEGF and pigment epithelium-derived factor 
expression ( 21 ). In the present study, we provide evidence 
for the role of the 12/15-LOX pathway in compromising 
retinal barrier function early during diabetes. Hence, in-
hibition of 12/15-LOX could potentially benefit the two 
main hallmark features of DR, i.e., barrier function disrup-
tion and pathological NV, which independently can lead 
to loss of vision among diabetics. 
 Next, the direct effects of specifi c 12/15-LOX-derived 
metabolites, 12- or 15-HETE, on retinal vasculature were 
demonstrated by two complementary approaches. First, the 
intravitreal injection of 12-HETE engendered many of the 
features characteristic of early DR, including pro-infl amma-
tory response and edema. Second, consistent with previous 
fi ndings ( 43 ), 12- or 15-HETE enhanced several in vitro en-
dothelial cell activities that are relevant to barrier function 
and angiogenesis, including reduced resistance, adhesion 
response to PMNs, migration, and tube formation. 
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cytoplasmic subunits, p47phox and p67phox. Our previ-
ous studies using animal and tissue culture models have 
shown that NOX2 is expressed at low levels in normal reti-
nas and in retinal endothelial cells maintained in control 
conditions, but is substantially increased in retinal ves-
sels of animals with diabetic or ischemic retinopathy and 
in retinal endothelial cells exposed to HG or hypoxia 
( 23–26 ). Furthermore, ROS derived from this enzyme 
stimulate diverse redox signaling pathways leading to an-
giogenesis-related gene induction as well as endothelial 
cell migration and proliferation ( 45 ). Therefore, in gain-
ing more insight into the mechanisms of eicosanoid-in-
duced angiogenesis, we expanded upon these studies to 
portray the causal relationship between NOX and 12- or 
15-HETE. Our in vitro studies demonstrated a couple of 
notable fi ndings: First, the potential angiogenic activity of 
12- or15-HETE in mediating both retinal endothelial cell 
migration as well as tube formation is regulated in a NOX-
dependent manner. Second, we broadened the scope to 
include other prominent features associated with endo-
thelial dysfunction, such as the secretion of infl ammatory 
cytokines and PMN adhesion. 12-HETE or15-HETE activates 
retinal endothelial cells toward a pro-infl ammatory phe-
notype characterized by increased release of IL-6, IL-8, 
and MCP-1, key regulators of leukocyte recruitment, and 
the subsequent augmentation of leukocyte adherence 
through a NOX-dependent mechanism. Together, our re-
sults point out that retinal microvascular changes that oc-
cur after 12- or 15-HETE challenge are mediated by NOX 
activity.  Figure 9 illustrates the interplay between these 
pathways and cross-talk with other cellular processes dur-
ing DR. 
 While the introduction of anti-VEGF therapies, ranibi-
zumab and afl ibercept, has shifted the treatment para-
digm for DR from laser photocoagulation in favor of this 
targeted approach, there are still major unmet needs and 
 Accordingly, the direct relationship between HRECs 
and eicosanoids has been explored through in vitro study. 
Previously, Cheranov et al. ( 44 ) reported that 15-HETE in-
duced migration and tube formation of HRECs through 
Src-mediated Rac1 activation. Rac1, in nonphagocytic 
cells, is a component of the multi-subunit enzyme, NOX, 
which is composed of the catalytic subunits NOX2 (for-
merly known as gp91phox) as well as p22phox, and the 
 Fig.  8.  NOX mediates the in vivo deleterious effect of 12-HETE 
on retinal vasculature. Fluorescein angiography (FA) of normal 
WT or NOX2   /   mice injected intravitreally with 12-HETE. The 
relative fl uorescence intensity of FA per mouse retina was calcu-
lated by the ImageJ software and normalized as a percentage to 
12-HETE-injected WT mice, arbitrarily set at 100%. Data shown are 
the mean ± SD and representative of four to six mice studied in 
each group. 
 Fig.  9. Cascade events involved in the pathogenesis 
of DR: Hyperglycemia activates the PLA2 to release 
AA from the retinal cell membrane. AA is then con-
verted to 12- or 15- HETE that generates ROS through 
NOX, creating a status of oxidative stress. This oxida-
tive stress leads to the activation of retinal endothelial 
cells through various infl ammatory signaling path-
ways, leading to leukocyte adhesion, hyperpermeabil-
ity, and ultimately NV (the cardinal signs of DR). 
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gaps in the understanding of underlying biological pro-
cesses. The potential long-term consequences of intraocu-
lar VEGF suppression on the retina have to be taken into 
account, because VEGF is a survival factor for retinal neu-
rons ( 46 ). Thereby, targeting a pathway that has crucial 
roles in compromising the vascular integrity in early DR 
would provide long-term retinal vascular benefi ts without 
affecting neighboring neurons. Our current and previous 
studies ( 22 ) suggest 12/15-LOX as a potential therapeutic 
target that mediates microvascular dysfunction in DR, 
probably via a NOX-dependent mechanism. Therefore, 
inhibition of the activated retinal 12/15-LOX system 
would allow the occurrence of a baseline level of VEGF to 
exert its direct neuroprotective effects and thus might pro-
vide a therapeutic strategy in modulating pathological 
pathways of DR when the VEGF level is not correlated with 
disease severity.  
 The authors would like to thank Dr. Krishna Maddipati for his 
assistance with the lipid analysis and discussion. 
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